Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Multimodal Cardiac Imaging of Immune-Mediated Complications Post Heart Transplantation: A Contemporary Review.

    Nov 26, 2025DOI: 10.1161/jaha.125.044160Journal ArticleAHA

    Written by: Bruno Bezerra LimaTam T DoanAtilla FeherJames C WilkinsonMarvin W KronenbergChloe CarrMalek NayfehTania RuizLuke L LawsMelissa Lou SilvaJohn A WellsLeandro SlipczukEmily T LippincottJohn J CarrKaushik AmancherlaCameron HenryDavid ParraKelly SchlendorfQuinn S WellsSean G HughesJonathan Soslow

    Find these authors on Roon

    KA
    Dr. Kaushik Amancherla
    Advanced Heart Failure · VUMC

    PATHOPHYSIOLOGY OF CARDIAC ALLOGRAFT VASCULOPATHY AND REJECTION

    Acute rejection includes acute cellular rejection (ACR) and antibody‐mediated rejection, both of which can occur at any time post transplant, though ACR is most common within the first year.8 ACR is a T‐cell–mediated myocarditis driven by direct allorecognition, where donor antigen‐presenting cells present alloantigens to recipient T cells, triggering clonal expansion and cytokine production (eg, IL‐2 [interleukin‐2], IFN‐γ [interferon‐gamma], TNF‐α [tumor necrosis factor alpha]). This recruits additional immune cells, including macrophages, eosinophils, and cytotoxic CD8+ T cells, which cause myocyte injury via effector molecules like perforin and granzyme. The resulting lymphocytic infiltration and myocyte damage lead to myocardial edema, impaired contractility, and, in severe cases, hemodynamic compromise (eg, reduced cardiac output).8Antibody‐mediated rejection arises from alloantibodies binding to donor antigens on the graft endothelium, activating the complement system (via classical, alternative, or mannan‐binding lectin pathways), with C4d deposition as a hallmark. This causes diffuse microvascular injury, endothelial inflammation, and immune complex deposition in capillaries. Complement activation amplifies damage by recruiting inflammatory cells and promoting tissue injury.9ACR is a T‐cell–mediated myocarditis driven by direct allorecognition, where donor antigen‐presenting cells present alloantigens to recipient T cells, triggering clonal expansion and cytokine production (eg, IL‐2 [interleukin‐2], IFN‐γ [interferon‐gamma], TNF‐α [tumor necrosis factor alpha]). This recruits additional immune cells, including macrophages, eosinophils, and cytotoxic CD8+ T cells, which cause myocyte injury via effector molecules like perforin and granzyme. The resulting lymphocytic infiltration and myocyte damage lead to myocardial edema, impaired contractility, and, in severe cases, hemodynamic compromise (eg, reduced cardiac output).8Antibody‐mediated rejection arises from alloantibodies binding to donor antigens on the graft endothelium, activating the complement system (via classical, alternative, or mannan‐binding lectin pathways), with C4d deposition as a hallmark. This causes diffuse microvascular injury, endothelial inflammation, and immune complex deposition in capillaries. Complement activation amplifies damage by recruiting inflammatory cells and promoting tissue injury.9Clinically, mild ACR or antibody‐mediated rejection may be asymptomatic, detectable only by endomyocardial biopsy, whereas severe episodes manifest as graft dysfunction (eg, heart failure, arrhythmias).8 Repeated or subclinical rejection episodes drive myocardial fibrosis and accelerate CAV, reflecting a continuum of immune‐mediated vascular and parenchymal damage.9, 10
    CAV is a chronic rejection process characterized by diffuse intimal hyperplasia in the coronary arteries of the cardiac graft, distinct from typical atherosclerosis that produces eccentric, focal plaques.11 It leads to concentric, longitudinally diffuse narrowing affecting both epicardial coronary arteries and the microvasculature, driven by endothelial injury from immune and nonimmune factors that promote inflammation, smooth muscle proliferation, and fibrosis in the vessel wall; donor‐specific antibodies and complement activation further exacerbate endothelial inflammation, and ischemia–reperfusion injury and metabolic stressors amplify this process, culminating in luminal obliteration and ischemia.9
    Early CAV is often asymptomatic due to cardiac denervation, allowing insidious progression, and the diffuse involvement results in balanced ischemia, which challenges detection with conventional tools.12 Standard angiography may appear normal until advanced stages, and stress tests can miss uniformly reduced perfusion; therefore, International Society for Heart and Lung Transplantation (ISHLT) guidelines recommend multimodal imaging for CAV surveillance (stress echocardiography, SPECT, PET, CMR, and CCTA), each with strengths and limitations (Table 1).6 CAV is staged by angiographic severity using the ISHLT classification (CAV 0–CAV 3), and modalities such as quantitative CMR perfusion and CCTA can enable earlier detection by capturing macrovascular and microvascular dysfunction (Table 2).6
    Multimodal Cardiac Imaging Techniques for CAV Detection Based on the International Society for Heart and Lung Transplantation Surveillance Recommendations12
    CAV indicates cardiac allograft vasculopathy.
    International Society for Heart and Lung Transplantation Classification of Cardiac Allograft Vasculopathy With Corresponding Findings Across Imaging Modalities12
    CAV indicates cardiac allograft vasculopathy; EF, ejection fraction; ISHLT, International Society for Heart and Lung Transplantation; LGE, late gadolinium enhancement; LM, left main coronary artery; and LV, left ventricle.
    Given these pathological features, different imaging modalities target different aspects of CAV and rejection. For CAV, anatomic imaging of coronaries (CCTA) can reveal luminal narrowing or wall thickening, whereas functional imaging (stress echocardiography, nuclear perfusion, CMR perfusion) can unmask ischemia or impaired flow reserve due to diffuse disease (Table 2). For rejection, tissue‐characterizing imaging (CMR with parametric mapping, PET metabolic imaging) can detect myocardial inflammation, and echocardiography can monitor functional changes such as new wall motion abnormalities or diastolic dysfunction (Table 3). Each modality has strengths and weaknesses, Table 4 highlights the comparative diagnostic performance of each modality across CAV stages, underscoring their differential value in early versus advanced disease.7
    Imaging Techniques for Acute Cardiac Allograft Rejection Based on ISHLT 2023 Surveillance Recommendations12
    ISHLT indicates International Society for Heart and Lung Transplantation; and TTE, transthoracic echocardiography.
    Diagnostic Performance of Noninvasive Imaging Modalities by CAV Stage
    CAV indicates cardiac allograft vasculopathy; CCTA, coronary computed tomography angiography; CMR, cardiac resonance imaging; EF, ejection fraction; MPI, myocardial perfusion imaging; and NPV, negative predictive value.

    ECHOCARDIOGRAPHY

    Transthoracic echocardiography is the primary imaging tool for routine surveillance post HTx due to its availability and real‐time assessment of chamber size, wall thickness, systolic/diastolic function, and valve performance.13 However, its sensitivity for detecting early CAV or mild rejection is limited. Heart transplant patients often exhibit high‐normal left ventricular ejection fraction (LVEF) at baseline due to surgical denervation and elevated catecholamines.26 Even with advanced CAV, EF may remain preserved; therefore, changes in EF are late and less sensitive than multiparametric assessment with strain and diastolic indices.14, 27 A decline in EF is more concerning: within the first year post transplant, it is likely to indicate acute rejection, whereas a later drop suggests CAV progression and strongly predicts adverse outcomes.14
    Diastolic function is critical to monitor. Transplanted hearts often show early impaired relaxation, which typically improves within 1 to 2 months. The development of a restrictive filling pattern (short deceleration time, elevated filling pressures) on serial echo should raise suspicion for rejection or CAV.14 Assessment is complicated by reduced atrial contribution (“atrial kick”) due to denervation and by exaggerated translational motion of the graft, which limit reliance on single Doppler indices. Tissue Doppler (e′) and left atrial strain help when interpreted longitudinally, although E/e′ alone is not a reliable surrogate of filling pressures in this setting.7, 14
    Speckle‐tracking echocardiography, measuring global longitudinal strain (GLS), enhances sensitivity by detecting subclinical dysfunction despite normal EF (Figure S1). Reduced GLS correlates with CAV burden and microvascular dysfunction, with worse GLS even in mild disease, and has prognostic value for graft outcomes. In rejection, GLS deterioration precedes EF decline; algorithms combining GLS with biomarkers improve negative predictive value and can reduce the need for biopsy.15
    Additional markers of rejection on resting echocardiography include myocardial thickening (edema), new or enlarging pericardial effusion, and global function changes; combining EF decline with new effusion is highly specific for moderate rejection, though strain detects earlier abnormalities.14
    Three‐dimensional (3D) echocardiography volumetric imaging improves reproducibility of LV volumes/EF and can assess dyssynchrony. In HTx patients, 3D speckle tracking has shown promise for detecting rejection, with abnormal GLS thresholds predicting biopsy‐proven rejection. Accordingly, 3D echocardiography complements 2‐dimensional strain for serial surveillance, particularly when image quality is adequate.
    Right ventricular (RV) indices (eg, tricuspid annular plane systolic excursion, RV systolic tissue Doppler velocity, RV free‐wall strain) can reveal graft dysfunction and pulmonary vascular load even when LV metrics are preserved. Although adult transplant‐specific data sets are more limited than in pediatrics, serial RV assessment can add sensitivity to comprehensive graft surveillance alongside LV strain and diastology.14, 15, 16, 28, 29
    Echocardiography is noninvasive, cost effective, and radiation free, ideal for frequent monitoring, including bedside use.13 Strain imaging improves sensitivity for diffuse myocardial changes, and in pediatrics, it avoids anesthesia.30 However, strain analysis is vendor and load dependent and requires high‐quality images and software. Strain and 3D techniques enhance sensitivity but remain dependent on image quality and expertise. Normal resting echocardiography does not exclude early CAV or rejection, underscoring the value of multimodality imaging when suspicion remains.7, 31
    Dobutamine stress echocardiography (DSE) is preferred for CAV screening due to the denervated heart’s delayed exercise response.32 ISHLT guidelines endorse DSE or treadmill stress for asymptomatic patients beyond the first year.33 DSE detects stress‐induced wall motion abnormalities, but its sensitivity for early CAV is low (~60%), with specificity of 80% to 90%.17 Adding speckle‐tracking strain may improve sensitivity by detecting subtle contraction changes. A normal DSE predicts low cardiac event rates, whereas abnormal results indicate higher revascularization needs and worse survival.
    Coronary flow velocity reserve (CFVR) by echocardiography is another stress echocardiography technique. To address diffuse microvascular disease and “balanced ischemia,” transthoracic Doppler (typically in the distal left anterior descending) or contrast‐enhanced techniques can quantify CFVR during vasodilator stress. In HTx recipients, reduced CFVR predicted long‐term outcomes and identified vascular dysfunction even when wall motion was normal. Beyond transplant, CFVR adds diagnostic and prognostic value over wall‐motion analysis alone; when CFVR is ≤2.0 to 2.5, suspicion for CAV should remain high despite a negative wall motion abnormality study.18
    DSE shares echocardiography’s general limitations (image quality, operator skill) and requires experienced teams for safe high‐dose dobutamine administration.34 False negatives occur in early diffuse CAV, though strain imaging may help.15 False positives may arise from hyperdynamic segments or septal tethering.35 Achieving adequate heart rate can be challenging due to denervation.36 DSE is not useful for acute rejection detection, as rejection typically causes global, not regional, dysfunction.14

    CARDIAC MAGNETIC RESONANCE

    CMR is a versatile imaging modality that provides high‐resolution views of cardiac anatomy and function, along with unique tissue characterization capabilities including edema, fibrosis, and perfusion imaging. In HTx patients, CMR can assess graft perfusion and detect rejection‐related myocardial changes. Initially, transplant‐focused CMR research aimed at noninvasively detecting acute rejection, but recent efforts have increasingly emphasized its use in assessing CAV. Functionally, CMR provides precise quantification of ventricular volumes, EF, and myocardial mass, particularly valuable when echocardiographic windows are suboptimal or distinguishing true dysfunction from technical artifact is challenging.3
    CMR excels at identifying myocardial edema (using T2‐weighted or T2 mapping sequences) and fibrosis (with late gadolinium enhancement [LGE] and T1 mapping). These techniques are directly relevant for evaluating acute rejection and chronic CAV‐induced myocardial changes.37
    Initial studies reported limited sensitivity of conventional CMR perfusion imaging for detecting CAV lesions apparent on angiography or IVUS. For example, a prior report found that many angiographic and IVUS‐proven lesions went undetected by qualitative perfusion CMR.38 However, advances in quantitative stress perfusion imaging have significantly improved detection (Figure 1). A previous study demonstrated that MPR measured by quantitative CMR correlates strongly with IVUS‐detected intimal thickening. An MPR threshold ≤1.68 identified significant CAV with 100% sensitivity and negative predictive value, making quantitative perfusion CMR a powerful noninvasive screening tool.21 A recent study by Lima et al. further supports this, showing that multiparametric CMR, incorporating stress MBF (≤1.95 mL/min per g), coronary flow reserve (≤1.97), native T1 (≥1030 ms), and T2 (≥51 ms), achieved 81.6% accuracy in detecting and grading CAV, with high sensitivity (20/23 cases) for moderate‐to‐severe CAV (ISHLT CAV 2/3) using a machine learning decision tree model, highlighting its potential to reduce reliance on invasive coronary angiography.22
    Left, rest and stress first‐pass perfusion images show myocardial segmentation for blood pool (yellow), endocardium (red), and epicardium (green) regions of interest. Middle, corresponding time–signal intensity curves for blood pool and myocardium are plotted at rest (top) and stress (bottom), with slopes derived for quantitative myocardial blood flow estimation. Right, the bull’s‐eye plot demonstrates globally reduced myocardial perfusion reserve index, with values ranging from 1.3 to 1.7, consistent with diffuse impairment of coronary flow reserve in advanced CAV. CAV indicates cardiac allograft vasculopathy; and MPRi, myocardial perfusion reserve index.
    Functional indices derived from cine magnetic resonance imaging, such as peak filling rate, are significantly reduced in patients with advanced CAV, reflecting underlying diastolic dysfunction associated with microvascular impairment.39 Similarly, myocardial strain analyses using tissue tagging or feature tracking have shown reduced early diastolic strain rates in transplant patients with microvascular dysfunction, reinforcing diastolic dysfunction as a sensitive marker for early‐stage CAV.21
    A comprehensive multiparametric approach combining perfusion, function, and LGE was found by a recent study to be more accurate than invasive angiography in identifying moderate CAV, highlighting the limitations of purely anatomical testing and the advantage of functional imaging in detecting diffuse early disease.12
    LGE remains valuable prognostically but is limited in detecting early, diffuse fibrosis typically seen in initial CAV. In contrast, T1 mapping and extracellular volume (ECV) mapping have emerged as promising tools for identifying early diffuse fibrosis associated with CAV. Elevated ECV values correlate with angiographic stenosis severity and biopsy‐proven fibrosis, suggesting potential utility as an early marker of disease progression.23
    CMR reliably detects myocardial edema associated with acute rejection via T2‐weighted imaging or quantitative T2 mapping. A recent meta‐analysis reported pooled sensitivities and specificities of ∼86% for T2‐based imaging techniques, underscoring their diagnostic value for rejection detection.3 Native T1 mapping and ECV have also demonstrated high sensitivity, though with somewhat lower specificity (Table 3).
    A recent single‐center study conducted a prospective trial demonstrating that a multiparametric CMR approach (T1, T2, ECV) safely replaced routine biopsies during first‐year surveillance, significantly reducing biopsy frequency without compromising patient outcomes. Their findings support CMR as a viable first‐line noninvasive rejection surveillance method.37
    CMR has practical limitations, including contraindications in patients with retained epicardial leads and the necessity of anesthesia or sedation in pediatric populations. Additionally, although CMR is costlier and less accessible than echocardiography, its comprehensive capability to assess anatomy, function, perfusion, viability, fibrosis, and inflammation within a single examination makes it invaluable for noninvasive transplant surveillance. Importantly, advanced quantitative stress perfusion and mapping techniques remain concentrated in experienced centers, and their availability is not yet widespread.

    NUCLEAR IMAGING (SPECT AND PET)

    Nuclear cardiology techniques provide significant value in assessing perfusion, metabolism, and immune activity in the transplanted heart. These SPECT myocardial perfusion imaging (MPI) with conventional SPECT radiotracers and PET MPI with radiotracers enabling MBF quantification. Next, we evaluate their roles in detecting CAV and acute rejection in HTx patients.

    SINGLE‐PHOTON EMISSION COMPUTED TOMOGRAPHY

    Myocardial perfusion SPECT employs gamma‐emitting tracers like thallium‐201 (201Tl) or technetium‐99m (99mTc) agents (sestamibi or tetrofosmin) to visualize stress (exercise or pharmacologic) and rest myocardial perfusion. In HTx patients, SPECT could be employed for CAV detection and risk stratification.
    SPECT MPI has modest sensitivity and specificity for advanced (CAV 2/3) disease but performs poorly in early (CAV 1) or microvascular‐predominant CAV.19 A normal pharmacologic stress SPECT with preserved LVEF suggests low likelihood of angiographic CAV, but diffuse, balanced ischemia typical of early disease can mask abnormalities, resulting in false‐negative scans.40 For instance, 99mTc‐tetrofosmin SPECT under adenosine stress missed cases of ≥70% stenosis in transplant patients, underscoring the limitation in diffuse disease.40
    Gated SPECT improves diagnostic value by combining perfusion with functional assessment: normal perfusion with normal wall motion makes significant CAV unlikely, whereas new wall motion abnormalities plus perfusion defects increase suspicion for obstructive CAV.41
    Emerging quantitative techniques. Solid‐state cadmium‐zinc‐telluride SPECT scanners allow dynamic acquisition and MBF quantification. In a small HTx study, dynamic cadmium‐zinc‐telluride SPECT using 201Tl or 99mTc tracers detected reduced MFR (<2.0) and moderate‐to‐severe angiographic CAV with accuracy comparable to 13N‐ammonia PET.42
    SPECT involves ionizing radiation (10–15 mSv with 99mTc) and pharmacologic stress agents (eg, adenosine), though it avoids nephrotoxic contrast. The lack of widely available MBF quantification with conventional SPECT means balanced ischemia remains a major blind spot. False negatives are common in early CAV, and cumulative radiation is a concern in younger patients undergoing serial scans. Accordingly, ISHLT guidelines state that SPECT has lower sensitivity than PET or CCTA for CAV detection and should mainly be reserved when invasive angiography, CCTA, or PET are not feasible.6

    POSITRON EMISSION TOMOGRAPHY

    PET offers superior sensitivity, resolution, and MBF quantification compared with SPECT, using tracers like 13N‐ammonia, 82Rubidium, or 18F‐fluorodeoxyglucose (18F‐FDG) for inflammation imaging. These attributes make PET ideal for detecting diffuse CAV and rejection‐related inflammation.
    Dynamic PET acquisition enables quantification of MBF at rest and stress, with MFR reflecting both epicardial and microvascular function.43 This ability to detect early, diffuse disease has earned PET a class IIa recommendation in ISHLT guidelines for CAV surveillance in experienced centers.6
    Several studies have validated PET against the invasive ISHLT grading system. A 2018 study showed stress MBF and MFR correlate with CAV grades 2–3 (area under the receiver operating curve 0.71–0.83 for MBF, 0.75–0.76 for MFR).44 Another study identified optimal cutoffs of <2.83 mL/g per min for stress MBF and <2.22 for MFR to detect moderate‐to‐severe CAV.45 A single center study proposed an integrated PET CAV score (MBF, perfusion, LVEF) that improved diagnostic performance (area under the receiver operating curve 0.88) (Figure 2).43 This approach was later validated with 82Rubidium‐PET, where PET CAV zero had a high negative predictive value.46 A recent Bayesian meta‐analysis including 44 studies and 3049 patients confirmed that PET CAV algorithms achieve pooled sensitivity 83.9% and specificity 89.6% for detecting significant CAV.20 Reported thresholds for abnormal MFR vary (<2.0 to <1.75), underscoring the need for center‐specific interpretation.47 Correlations between PET flow metrics and IVUS measures of intimal thickening and plaque volume further support the biological relevance of quantitative PET.48
    Regional myocardial perfusion is classified as normal or abnormal based on global peak MBF and EF. Normal perfusion with MBF ≥1.70 and EF >45% indicates CAV 0 (no stenosis); MBF ≥1.70 with EF ≤45% suggests CAV 1 (mild). Abnormal perfusion splits into single‐vessel (MBF ≥1.70: CAV 1; MBF <1.70: CAV 2/3) or multivessel (CAV 2/3). Adapted from a previously published algorithm (2018).43 CAV indicates cardiac allograft vasculopathy; EF, ejection fraction; and MBF, myocardial blood flow.
    Absolute flow values, although useful, are limited by variability. Test–retest studies in nontransplant populations show 20% to 25% differences in MBF.49 Because transplant‐specific reproducibility data are scarce, small changes around this margin should be interpreted with caution. In clinical practice, serial changes in MFR are more reliable than a single measurement, provided acquisition methods are consistent. Interpretation also depends on graft physiology. Flow and reserve typically rise modestly in the early posttransplant period, stabilize, and then decline with the progression of microvascular and epicardial disease.50, 51 These longitudinal shifts reinforce the need for baseline studies and serial follow‐up rather than rigid universal cutoffs.
    PET also carries strong prognostic value. Reduced MFR consistently predicts major adverse events, with cutoffs ≤1.75 to 2.0 linked to worse survival, more hospitalizations, and higher risk of retransplantation.45, 52 The PET CAV score further enhances risk stratification and has been externally validated.43, 46
    Serial PET strengthens this prognostic role. Persistently low or worsening MFR is associated with poor outcomes, whereas transient improvement is reassuring.51, 52, 53 Longitudinal changes in myocardial blood flow have been explored across eras. A 1998 study first demonstrated progressive decline in flow reserve beyond the first posttransplant year, suggesting cumulative microvascular injury,54 which a more recent report confirmed that trajectories of declining MFR strongly predict CAV progression and adverse outcomes.50 These findings reinforce the value of serial quantitative PET follow‐up rather than single‐time‐point assessment. Importantly, recurrent rejection episodes accelerate CAV and lower MFR, linking PET‐derived flow abnormalities with immune‐mediated injury.44, 52
    In sum, PET provides a robust, noninvasive method to diagnose, monitor, and risk‐stratify CAV in transplant recipients, with serial trajectories offering the most clinically meaningful information. Test–retest variability for absolute MBF is ~20% to 25% in nontransplant cohorts; transplant‐specific reproducibility data are sparse.49 Therefore, small serial changes near this margin should be interpreted with caution, emphasizing MFR trajectories and consistent acquisition/reconstruction. Because graft physiology evolves, flow and reserve tend to rise modestly early after HTx, then stabilize and decline with microvascular/epicardial disease, center‐specific longitudinal interpretation is preferable to rigid universal cutoffs.51, 53
    PET’s high cost, limited availability, and complex acquisition (eg, cyclotron for 13N‐ammonia or expensive 82Rubidium generators) restrict its use.16 For instance a recent report highlights the limited availability of PET (55%) in HTx performing centers across the United States in comparison to the wide availability of CMR (85%) and CCTA (91%).55 In addition, expertise is needed to interpret diffuse reduction in MFR, which may not always indicate CAV.
    18F‐FDG PET metabolic imaging is most currently employed for detection of myocardial inflammation, endocarditis and cardiac sarcoidosis. Murine studies report diffuse myocardial FDG uptake, especially in the right ventricle (RV standardized uptake value ratio >2.0), which strongly correlates with biopsy‐proven rejection, with 92% of rejection cases showing heterogeneous or diffuse uptake versus 2% in nonrejection cases.56 However, the application in humans is limited to case reports and small series.57, 58 To date, the largest clinical series from the United Kingdom evaluated 30 HTx patients (including 12 patients with definite and 18 with suspected rejection) who underwent 18F‐FDG PET.58 Importantly, all patients with definite rejection showed increased myocardial 18F‐FDG uptake, and in 5 cases, myocardial avidity was present beyond 6 weeks despite antirejection therapy. Overall, 18F‐FDG PET is a promising tool for the detection of acute cellular rejection; however, further studies are needed to validate these observations.

    CARDIAC COMPUTED TOMOGRAPHY ANGIOGRAPHY

    CCTA is increasingly used in the noninvasive assessment of CAV. Modern dual‐source and wide‐detector CT scanners, equipped with advanced motion‐correction algorithms, can reliably produce diagnostic‐quality images even at elevated heart rates (80–100 bpm). This technological improvement significantly reduces the dependence on aggressive heart rate control using β‐blockers or ivabradine, which is particularly beneficial given the chronically elevated heart rates typical in denervated HTx recipients.59
    Current CCTA imaging protocols generally use low tube voltage (kVp) combined with high‐pitch scanning, thereby substantially decreasing both iodinated contrast volume (usually 50–70 mL) and radiation exposure. This approach makes CCTA a practical option in most patients; however, centers typically avoid using this modality in individuals with significantly impaired renal function (estimated glomerular filtration rate <30 mL/min per 1.73 m2) to mitigate the risk of contrast‐induced nephropathy. Modern radiation doses with prospective ECG‐gating or high‐pitch acquisitions routinely range between 2 and 5 mSv, significantly lower than those typically encountered during conventional invasive coronary angiography.59 Furthermore, the development of low‐dose scanning techniques and iterative reconstruction algorithms has rendered CCTA increasingly feasible for pediatric transplant patients, provided heart rate control is acceptable.
    Regarding the diagnostic accuracy of CCTA for detecting significant CAV, a pooled meta‐analysis of 13 prospective studies involving 615 HTx recipients demonstrated high sensitivity (94%–97%) and specificity (81%–92%) for identifying coronary stenoses ≥50%. Additionally, the negative predictive value was consistently excellent (approximately 99%), confirming CCTA’s strength as a reliable noninvasive test to rule out significant coronary disease.59 Recent advances have also incorporated dynamic CT‐MPI, which further enhances CCTA’s diagnostic performance. In a study involving 63 transplant recipients, a combined assessment using anatomical stenosis on CCTA and myocardial blood flow measurements from dynamic CT‐MPI significantly improved detection of both epicardial and microvascular CAV, achieving an area under the receiver operating curve of 0.89, with sensitivity and specificity values of 74% and 96%, respectively.24
    CT‐derived fractional flow reserve (FFRct) represents another promising advancement that enables physiological lesion assessment from anatomical data without additional invasive testing or significant radiation exposure (<0.5 mSv) (Figure 3). A recent HTx cohort study demonstrated focal flow‐limiting lesions (FFRct ≤0.80) in ∼25% of patients. Importantly, even in those without significant focal disease, distal FFRct values were frequently reduced, highlighting the ability of FFRct to detect and quantify the diffuse microvascular dysfunction characteristic of CAV.25
    Left: No evidence of plaque or stenosis (Coronary Artery Disease Reporting and Data System 0/CT‐CAV 0), with normal FFRct values (eg, 0.97 in the LAD artery). Middle: Mild CAV 1 (25%–49% lumen diameter reduction), showing low‐normal distal FFRct values (eg, 0.81 in the LAD and 0.88 in the mid RCA). Right: Severe CAV 2/3 with chronic total occlusion of the proximal RCA and severe (70%–99%) stenosis of the left main, with markedly abnormal distal FFRct values (eg, 0.55 in the distal LAD and 0.64 in the distal left circumflex artery). CAV indicates cardiac allograft vasculopathy; CT, computed tomography; FFRct, computed tomography‐based fractional flow reserve; LAD, left anterior descending; and RCA, right coronary artery.
    Beyond lumenography and functional assessment, high‐resolution CCTA data sets allow detailed plaque characterization and quantification of vessel‐wall thickening. Specific plaque morphologies, such as concentric fibrous thickening or low‐attenuation plaque detected by CCTA correlate strongly with IVUS‐measured intimal thickening and may provide early indicators of angiographically silent CAV.59
    Despite these considerable advantages, several limitations persist. The requirement for iodinated contrast medium limits CCTA uses in patients with severely impaired renal function. Additionally, although contemporary radiation doses are modest, the risk remains relevant. Heavy calcification can cause blooming artifacts that overestimate stenosis severity, and diffuse microvascular disease without lumen narrowing may remain undetected unless supplemented by CT‐MPI or other functional imaging. Furthermore, patients with pacemakers or other implanted devices or advanced renal dysfunction presenting potential streak artifacts may pose ongoing challenges in image interpretation. Finally, although radiation and contrast doses are now modest, chronic kidney disease is common in HTx populations, making repeated annual CCTA impractical; hence, rather than serial, its use should be strategic for anatomic clarification, plaque characterization, or when functional tests are equivocal. Despite excellent negative predictive value, CCTA is not typically used for annual serial surveillance; it is best deployed strategically for anatomic clarification, plaque characterization, or when functional testing is equivocal.25

    SPECIAL CONSIDERATIONS IN PEDIATRIC HTx IMAGING

    Pediatric HTx recipients experience similar immune‐mediated complications as adults, including acute rejection and CAV but face unique challenges. Children’s longer life expectancy allows chronic conditions like CAV to progress, often aggressively due to heightened immune responses.60 Surveillance adjusts for age, as infants and young children cannot report symptoms or cooperate with tests, increasing risks of invasive procedures like biopsies and angiograms due to anesthesia and smaller anatomy.5 Accordingly, noninvasive imaging plays a central role in surveillance thus preferred to minimize these risks, with echocardiography and CMR serving as primary tools. Because several imaging principles parallel those in adults, this section focuses primarily on pediatric‐specific considerations such as sedation requirements, age‐related normative data, and feasibility. Where applicable, findings reference adult data to avoid repetition.

    ECHOCARDIOGRAPHY IN PEDIATRIC HTx RECIPIENTS

    Transthoracic echocardiography is the first‐line modality in pediatric HTx follow‐up, safe and feasible without sedation across all ages.5 Many centers perform routine echocardiograms at clinic visits, reserving invasive studies for cases with abnormal echocardiographic findings or clinical concerns beyond early posttransplant checks. Traditional measures such as LVEF are insensitive to early graft dysfunction, often remaining preserved in early rejection or CAV, although reduced LVEF or new effusions often detect severe rejection. Echocardiographic markers are essential tools in the surveillance of immune‐mediated complications and risk stratification in pediatric HTx recipients.61
    Strain echocardiography provides early detection of graft dysfunction; both longitudinal and circumferential strain values change dynamically with rejection and recovery, supporting their use for serial monitoring.62 GLS is a sensitive marker of subclinical myocardial dysfunction and may indicate both rejection63 and CAV.64 GLS was noted to be impaired universally in the early posttransplant period with gradual recovery, suggesting that perioperative factors may influence strain and that GLS should be interpreted within the clinical context.65 A lack of improvement in GLS after transplantation and persistently low GLS at follow‐up may predict mortality and graft failure.27 GLS declines significantly during episodes of rejection, and predefined strain thresholds can distinguish between rejection and nonrejection states.66 Additionally, a study demonstrated significant declines in global circumferential strain in patients with biopsy‐proven rejection, whereas patients without rejection showed improved values. These findings suggest that dynamic changes in strain, rather than absolute thresholds, may be more reflective of evolving pathology.62 Rotational mechanics such as LV twist and untwist may be considered as advanced markers of myocardial performance. Abnormal torsion and rotational deformation have been observed during episodes of rejection and in association with CAV.67 However, these parameters remain investigational at this time.27
    Three‐dimensional echocardiography, including 3D speckle‐tracking echocardiography, has emerged as a valuable adjunct in the surveillance of pediatric HTx recipients. A 2017 study evaluated 60 children and young adults with HTx and found that, despite preserved EF, patients demonstrated significantly reduced LV longitudinal and circumferential strain, impaired RV strain, and diminished LV twist and torsion compared with controls. Notably, LV systolic dyssynchrony was present in 20% of transplant recipients.68 Similarly, a 2020 report investigated 30 clinically well pediatric HTx patients and reported decreased LV GLS and reduced RVEF and free‐wall strain, whereas LV circumferential strain and EF remained preserved.69 Importantly, 3D speckle‐tracking echocardiography demonstrated good intra‐ and interobserver reproducibility, supporting its feasibility in clinical practice. Collectively, these findings indicate that 3D echocardiography can identify subclinical biventricular dysfunction and mechanical dyssynchrony not evident on conventional measures, underscoring its potential role in longitudinal surveillance, although larger studies are needed to establish prognostic significance.70
    Myocardial performance index, or the Tei index, combines isovolumetric contraction and relaxation times relative to ejection time and has shown modest correlation with rejection events.71 Although useful when integrated into multiparametric surveillance strategies, it may lack specificity as a standalone marker.
    Myocardial work considers both myocardial deformation (GLS) and systemic blood pressure, and therefore, potentially provides a more precise assessment of myocardial function. A 2022 report showed that global myocardial work efficiency was significantly reduced in pediatric patients with CAV, even when EF and GLS were preserved, suggesting that myocardial work efficiency may detect subclinical disease not apparent on conventional imaging, adding important values to noninvasive assessment and may improve early detection of graft dysfunction.72
    Diastolic function is considered a surrogate for pediatric allograft function. Similar markers of diastolic dysfunction have been studied in pediatric HTx recipients. Tissue Doppler imaging measures velocity of myocardial motion and has been shown as a marker of allograft dysfunction. Abnormal tissue Doppler imaging parameters—such as decreases in early diastolic (e′) or systolic velocities—have been associated with acute rejection and adverse outcomes.73, 74 Several noninvasive parameters have been studied as indicators of elevated LV end‐diastolic pressure or pulmonary capillary wedge pressure (PCWP). The ratio of transmitral inflow velocity (E) to LV diastolic strain rate was reported as a better predictor of elevated PCWP and adverse events compared with the traditional E/e’ ratio.61 Left atrial strain, particularly during the reservoir phase, has also shown to strong correlation with invasively measured PCWP and demonstrated good discriminatory performance in identifying acute rejection and CAV.75 Increased LV diastolic stiffness has been associated with lower cardiac index and reduced exercise capacity.61
    RV function parameters have also demonstrated sensitivity to graft dysfunction. Tricuspid annular plane systolic excursion, RV systolic tissue Doppler velocity, and RV free‐wall strain can identify rejection‐related abnormalities, particularly in pediatric patients who may have relatively preserved LV function.27 A study comparing RV function in clinically well HTx recipients to controls found significant differences in tricuspid annular plane systolic excursion and systolic tissue Doppler velocity with preserved fractional area change, suggesting persistent subclinical RV dysfunction post transplant and fractional area change may be important metrics for surveillance of RV function in this population.76 Serial RV assessment, as shown by a 2022 study, can help detect episodes of ACR and may offer additive value to standard surveillance protocols, although their long‐term prognostic value remains underexplored.77 Nevertheless, serial evaluation of RV function is beneficial in comprehensive graft surveillance.
    Stress echocardiography using dobutamine or exercise protocols has been used to unmask subclinical ischemia due to CAV, with myocardial contrast echocardiography showing feasibility for perfusion defect detection, though data are limited.78 Myocardial contrast echocardiography allows for assessing perfusion at the microvascular level. A 2021 study demonstrated that real‐time myocardial contrast echocardiography during dobutamine stress was safe and feasible in pediatric HTx recipients, showing high specificity (94%) and diagnostic accuracy (89%) for detecting CAV.79 Additionally, MPR was significantly lower in patients with angiographic CAV, highlighting its prognostic relevance. Exercise stress echocardiography also holds promise based on data from an a large single‐center study, showing a positive exercise stress echocardiography was associated with a 3.5‐fold increased risk of cardiovascular events, whereas a negative test predicted favorable outcomes—even in patients with normal angiograms.80 Exercise and perfusion‐based assessments, including exercise stress echocardiography and real‐time myocardial contrast echocardiography, may provide insights for detecting CAV and stratifying long‐term cardiovascular risk.80 These modalities capture physiologic responses that static imaging may miss, particularly in detecting microvascular or early epicardial CAV.81
    Despite these advancements, traditional Doppler parameters continue to show limitations, especially in the detection of early rejections.77, 81 A prior report demonstrated that neither Doppler‐derived nor catheter‐derived hemodynamic indices reliably predicted rejection, suggesting limitations in standalone use.74 A 2024 study found that commonly used metrics such as mitral E/A, E/e′, and deceleration time did not correlate with invasively measured LV end‐diastolic pressure or PCWP, highlighting the need for more reliable noninvasive surrogates in long‐term follow‐up.82 It is also important to note that pediatric GLS norms may vary by age and body size, requiring careful interpretation.70
    In summary, echocardiography remains the most widely used noninvasive tool in pediatric HTx surveillance, but traditional Doppler indices and strain measures showed limited reliability as stand‐alone markers, emphasizing the need for multiparametric and clinical context‐specific interpretation for acute rejection (AR) and CAV. Importantly, stress echocardiography protocols and adjuncts such as myocardial contrast imaging offers a promising safe, noninvasive, and prognostically meaningful approach for detecting subclinical and microvascular CAV in pediatric HTx recipients, complementing anatomic imaging by capturing physiologic disease expression that static modalities may miss.

    CMR IN PEDIATRIC HTx RECIPIENTS

    CMR imaging is a comprehensive, noninvasive modality that offers robust assessment of anatomy, function, and tissue characterization without ionized radiation exposure. Multiparametric CMR—including T1 and T2 mapping, ECV, and LGE—has shown high diagnostic yield for detecting rejection and monitoring graft integrity, whereas sedation needs in younger children may pose challenges.5 T2 mapping can detect rejection, with small studies showing high negative predictive value.83 Perfusion CMR, feasible in cooperative older children, may screen for CAV, with qualitative perfusion deficits correlating with angiographic findings.84 CMR provides more reliable ventricular volumes and EF than echocardiography, but device implants and sedation requirements may limit its use.5 Multicenter trials are underway to validate CMR in the pediatric HTx recipient population.
    CMR mapping techniques have shown promise in identifying acute rejection (Figure S2). Soslow et al. found elevated native T1, T2, and ECV in pediatric patients with biopsy‐proven or clinically diagnosed rejection.85 A recent investigation demonstrated that T1 mapping, particularly the number of focal T1 hotspots, declined after treatment of rejection episodes, although T2 values were less dynamic.86 A 2020 study also reported significantly elevated T2 values in patients with rejection, with higher T2 levels correlating with higher biopsy grades.87 A 2023 report identified elevated native T1, T2, and ECV as predictors of adverse outcomes. High native T1 was linked to a 4‐fold increased risk of hospitalization or retransplantation.88 A 2024 multicenter study grouped pediatric HTx recipients into AR, CAV, and healthy cohorts. Patients with AR had significantly higher ECV, T1, and T2 Z scores, consistent with myocardial edema. Notably, global circumferential strain was impaired in both groups with AR and CAV, despite preserved LVEF in CAV, suggesting subclinical myocardial dysfunction. The authors emphasized that abnormal strain and parametric mapping findings can differentiate between AR and CAV, potentially guiding earlier intervention.89
    CMR provides important insights for chronic graft surveillance. A 2017 study showed ECV correlated with myocardial collagen volume fraction and BNP (B‐type natriuretic peptide) levels, even in asymptomatic children.90 Another report found LGE in 36% of patients, associated with older age, increased LV volumes, and reduced EF.91 A more recent analysis linked elevated ECV and T2 values in patients with a history of rejection and histologic fibrosis, correlating with adverse ventricular remodeling.92
    Tissue phase mapping via CMR provides quantitative measurements of myocardial velocities, rotational mechanics, and ventricular synchrony. A 2020 report found significantly reduced long‐axis and radial myocardial velocities in pediatric HTx recipients, as well as increased intra‐ and interventricular dyssynchrony compared with healthy controls.93 These abnormalities were associated with the number of prior rejection episodes, suggesting a role for tissue phase mapping in longitudinal graft surveillance.
    Moreover, CMR‐derived diastolic indices correlate strongly with invasively measured filling pressures. A 2022 study found that parameters such as peak filling rate, GLS, and indexed left atrial volume were significantly associated with PCWP and right atrial pressure.94 A combined model of GLS and peak filling rate predicted elevated PCWP with high diagnostic accuracy (area under the receiver operating curve 0.84), highlighting the utility of CMR in noninvasive hemodynamic evaluation.
    CAV remains a leading cause of graft failure and late mortality. It often begins as diffuse microvascular disease and progresses insidiously. Stress perfusion CMR (spCMR) imaging offer promises for evaluating myocardial and microvascular perfusion in this high‐risk population.
    The feasibility of spCMR using adenosine was demonstrated in a prospective cohort of 16 pediatric HTx patients, including those with angiographically confirmed CAV and matched controls.95 The study showed that spCMR is safe, reproducible, and has excellent inter‐ and intraobserver agreement. Although median MPR was lower in patients with CAV compared with controls (1.43 versus 1.48), the difference was not statistically significant. Importantly, both groups had lower MPR values compared with normative adult data, raising concern for a potentially high burden of subclinical microvascular dysfunction in pediatric HTx recipients regardless of angiographic findings.95
    To improve the tolerability and practicality of stress testing in children, regadenoson, a selective A2A adenosine receptor agonist, has been increasingly used. Unlike adenosine, regadenoson requires only a single intravenous line and has a more favorable side effect profile. In a retrospective review of 39 pediatric patients, a 2022 series demonstrated the safety and efficacy of regadenoson spCMR combined with motion correction and semiquantitative analysis.96 Among the 16 pediatric HTx recipients in the cohort, global MPR index was significantly lower compared with nontransplant controls (0.75±0.22 versus 0.92±0.23, P=0.03), consistent with microvascular impairment. No major adverse events were reported, further supporting the safety and feasibility of quantitative spCMR in this population. MPR in pediatric Tx recipients are lower compared with controls, and lowest in those having more rejection episodes, indicating potential prognostic utility.95
    To extend these findings to younger and sedated patients, a recent report evaluated regadenoson spCMR in 46 pediatric HTx patients undergoing imaging under general anesthesia. The mean age was 7.8 years, with all patients successfully completing the scan. Although transient hypotension occurred in 77% of the scans, it was effectively managed with phenylephrine, and no major adverse events occurred. Comparison with a nongeneral anesthesia cohort revealed no significant differences in MPR index or rates of qualitative perfusion defects, confirming that spCMR under general anesthesia yields diagnostically equivalent data in younger patients.97
    In summary, spCMR is a safe, feasible, and informative tool for assessing myocardial perfusion in pediatric HTx recipients. It enables the detection of subclinical microvascular disease, which can be difficult by angiography, and can be applied across a wide pediatric age range. Incorporation of spCMR into transplant surveillance protocols may enhance early detection, intensify surveillance and medical management, and guide timely intervention in CAV.88, 95
    Although CMR is a powerful, noninvasive imaging tool for detecting AR, chronic graft injury, including CAV, in pediatric HTx patients, sedation requirements in younger children limited its availability and contraindications (such as implanted devices) are practical barriers.
    In conclusion, CMR with T1 and T2 mapping, ECV, and strain analysis can identify subclinical graft pathology, reduce reliance on biopsy, and inform prognosis. As data accumulate, CMR is poised for increasing integration into routine pediatric HTx surveillance protocols. SpCMR has emerged as a safe, feasible, and reproducible tool for pediatric HTx surveillance, enabling early detection of microvascular dysfunction and subclinical CAV across a wide age range and offering prognostic insights that can complement or reduce reliance on invasive angiography.

    NUCLEAR IMAGING AND CCTA IN CHILDREN

    Nuclear imaging, like SPECT or PET, is rarely used due to radiation concerns but may be considered when CMR is not feasible.5 Low‐dose 13N‐ammonia PET can assess myocardial flow reserve in adolescents, correlating abnormal findings with worse IVUS results, though pediatric data are sparse. FDG PET for rejection is challenging due to dietary and compliance issues in children. As in adults, nuclear imaging is best reserved for select cases, and routine or serial use is not recommended in the pediatric population.
    CCT is increasingly used for CAV detection due to its high resolution, capable of assessing small coronary arteries.5 Modern scanners reduce radiation to single‐digit mSv, making CT viable for pediatric use.98 CT detects larger CAV lesions but is less sensitive than IVUS for subtle changes.99 Calcium scoring may rule out significant CAV in older children, though breath‐holding or controlled ventilation remains a challenge.100 CT, like nuclear imaging, should be applied judiciously in pediatrics and is not suited for routine annual surveillance.
    Compared with adults, pediatric imaging faces additional challenges including smaller body size, higher heart rates, and frequent sedation requirements. Nonetheless, advances in motion correction, rapid acquisition, and child‐adapted protocols are improving feasibility. Table 5 outlines these challenges with proposed solutions. Echocardiography remains the cornerstone of pediatric transplant imaging, with advanced modalities like strain, CMR, and CT reducing reliance on invasive methods. Although adult findings guide pediatric approaches, evidence in children is limited, necessitating multicenter studies to validate noninvasive techniques.5
    Pediatric‐Specific Challenges
    CMR indicates cardiac magnetic resonance; GLS, global longitudinal strain; and LAS, left atrial strain.

    CONCLUSIONS

    Late complications of HTx, including CAV and chronic rejection, remain challenging to diagnose. Invasive coronary angiography and biopsy are reference standards but are limited by risks and imperfect sensitivity. Advances in noninvasive imaging now allow assessment of structure, function, perfusion, and even immune activity. Although no single test can capture all aspects of disease, each modality contributes complementary information.
    The most effective surveillance will likely combine modalities. Echocardiography with strain offers accessible screening, PET and CMR add tissue characterization, and CCTA provides high‐resolution anatomy. Used together, these techniques reduce reliance on routine invasive testing and allow individualized risk stratification. Advanced quantitative methods, such as PET MBF or perfusion CMR, are promising but currently concentrated in expert centers and require broader validation.
    Future strategies will likely adopt tiered algorithms: low‐cost screening with echocardiography ± biomarkers, advanced imaging for confirmation, and invasive procedures reserved for high‐risk findings. In pediatrics, where avoiding invasive tests is especially important, adapting and validating these approaches across multicenter studies is essential.
    In summary, noninvasive imaging has moved to the center of transplant surveillance. When applied in combination, modalities such as echocardiography, PET, CMR, and CT increasingly limit the need for routine biopsies and angiography. As technology matures and evidence expands, the standard of care will likely shift toward predominantly noninvasive strategies, improving safety and quality of life while maintaining vigilant graft monitoring.

    Sources of Funding

    Vanderbilt (C‐SPaRC) Pilot Grant (Bruno Bezerra Lima).

    Disclosures

    None.

    Supporting information

    Figures S1–S2
    KADr. Kaushik Amancherla

    Dr. Kaushik Amancherla

    Cardiology · Advanced Heart Failure & Transplantation
    Vanderbilt University Medical Center
    kaushik